Cyclo Therapeutics, Inc. Common Stock
CYTH
CYTH was delisted on the 25th of March, 2025.
9 hedge funds and large institutions have $2.58M invested in Cyclo Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 9 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$469K |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$416K |
| 3 |
Jane Street
New York
|
+$131K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$73.5K |
| 5 |
Goldman Sachs
New York
|
+$48.3K |
Top Sellers
CYTH Hedge Fund Activity: Q4 2020 in Review
9 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Cyclo Therapeutics, Inc. Common Stock (CYTH) for Q4 2020, worth a combined $2.58M.
Buyers outnumbered sellers: 9 funds opened new CYTH positions and 0 closed out — a net gain of 9 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $469K.
- 9 institutional investors held Cyclo Therapeutics, Inc. Common Stock (CYTH) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $2.58M of Cyclo Therapeutics, Inc. Common Stock stock for Q4 2020.
- 9 funds opened new Cyclo Therapeutics, Inc. Common Stock positions in Q4 2020 and 0 closed out, a net change of +9 holders.
- The largest Cyclo Therapeutics, Inc. Common Stock buyer in Q4 2020 was Armistice Capital, an estimated $469K added.
Based on aggregated 13F filings for Q4 2020.